First-in-Human cell therapy tested for tough autoimmune cases

NCT ID NCT07123519

Recruiting now Disease control Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This is an early-stage safety study testing a new cell therapy called YTS109. It will give a single infusion of these cells to 18 adults with severe autoimmune diseases, like lupus or Sjogren's, that have not responded to standard treatments. The main goal is to see if the treatment is safe, while also checking for any early signs that it might help control the diseases.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATORY MYOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, China
RECRUITING

Tianjin, China

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS ANTIPHOSPHOLIPID SYNDROME (APS) INFLAMMATORY MYOPATHY LUPUS NEPHRITIS (LN) SJOGREN'S SYNDROME (SS) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)